Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.drudis.2020.06.014 http://scihub22266oqcxt.onion/10.1016/j.drudis.2020.06.014 32569833!7305737!32569833     free     free     free       Drug+Discov+Today 2020 ; 25 (10): 1775-1781 Nephropedia Template TP {{tp|p=32569833|t=2020. Exportin 1 inhibition as antiviral therapy |pdf=|usr=}}{{32569833}} gab.com Text Exportin 1 inhibition as antiviral therapy JO: Drug Discov Today http://www.kidney.de/pget.php?&tw=1&pmid=32569833 #FOAvip Coronavirus 2019 (COVID-19; caused by Severe Acute Respiratory Syndrome Coronavirus 2; SARS-CoV-2) is a currently global health problem. Previous studies showed that blocking nucleocytoplasmic transport with exportin 1 (XPO1) inhibitors originally developed as anticancer drugs can quarantine key viral accessory proteins and genomic materials in the nucleus of host cell and reduce virus replication and immunopathogenicity. These observations support the concept of the inhibition of nuclear export as an effective strategy against an array of viruses, including influenza A, B, and SARS-CoV. Clinical studies using the XPO1 inhibitor selinexor as a therapy for COVID-19 infection are in progress. Twit Text FOAVip Exportin 1 inhibition as antiviral therapy ????Drug Discov Today http://www.kidney.de/pget.php?&tw=1&pmid=32569833 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32569833 #FOAvip English Wikipedia <ref>{{Cite pmid|32569833}}</ref> Exportin 1 inhibition as antiviral therapy #MMPMID32569833 Uddin MH; Zonder JA; Azmi AS Drug Discov Today 2020[Oct]; 25 (10): 1775-1781 PMID32569833show ga Coronavirus 2019 (COVID-19; caused by Severe Acute Respiratory Syndrome Coronavirus 2; SARS-CoV-2) is a currently global health problem. Previous studies showed that blocking nucleocytoplasmic transport with exportin 1 (XPO1) inhibitors originally developed as anticancer drugs can quarantine key viral accessory proteins and genomic materials in the nucleus of host cell and reduce virus replication and immunopathogenicity. These observations support the concept of the inhibition of nuclear export as an effective strategy against an array of viruses, including influenza A, B, and SARS-CoV. Clinical studies using the XPO1 inhibitor selinexor as a therapy for COVID-19 infection are in progress. |*COVID-19 Drug Treatment[MESH] |*Drug Design[MESH] |Active Transport, Cell Nucleus[MESH] |Animals[MESH] |Antiviral Agents/*therapeutic use[MESH] |COVID-19/immunology/metabolism/virology[MESH] |Cell Nucleus/*drug effects/immunology/metabolism/virology[MESH] |Exportin 1 Protein[MESH] |Host-Pathogen Interactions[MESH] |Humans[MESH] |Karyopherins/*antagonists & inhibitors/metabolism[MESH] |Molecular Targeted Therapy[MESH] |Receptors, Cytoplasmic and Nuclear/*antagonists & inhibitors/metabolism[MESH]Exportin 1 inhibition as antiviral therapy (epmc).pdf DeepDyve Pubget Overpricing